Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials

Molecules. 2019 Apr 12;24(8):1459. doi: 10.3390/molecules24081459.


Cannabidiol (CBD) is one of the cannabinoids with non-psychotropic action, extracted from Cannabis sativa. CBD is a terpenophenol and it has received a great scientific interest thanks to its medical applications. This compound showed efficacy as anti-seizure, antipsychotic, neuroprotective, antidepressant and anxiolytic. The neuroprotective activity appears linked to its excellent anti-inflammatory and antioxidant properties. The purpose of this paper is to evaluate the use of CBD, in addition to common anti-epileptic drugs, in the severe treatment-resistant epilepsy through an overview of recent literature and clinical trials aimed to study the effects of the CBD treatment in different forms of epilepsy. The results of scientific studies obtained so far the use of CBD in clinical applications could represent hope for patients who are resistant to all conventional anti-epileptic drugs.

Keywords: cannabidiol; clinical trials; treatment-resistant epilepsy.

Publication types

  • Review

MeSH terms

  • Anti-Anxiety Agents / adverse effects
  • Anti-Anxiety Agents / chemistry
  • Anti-Anxiety Agents / therapeutic use*
  • Anticonvulsants / adverse effects
  • Anticonvulsants / chemistry
  • Anticonvulsants / therapeutic use*
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / chemistry
  • Antipsychotic Agents / therapeutic use*
  • Cannabidiol / adverse effects
  • Cannabidiol / chemistry
  • Cannabidiol / therapeutic use*
  • Cannabis / chemistry*
  • Clinical Trials as Topic
  • Epilepsy / drug therapy*
  • Epilepsy / pathology
  • Epilepsy / physiopathology
  • Humans
  • Seizures / drug therapy*
  • Seizures / pathology
  • Seizures / physiopathology


  • Anti-Anxiety Agents
  • Anticonvulsants
  • Antipsychotic Agents
  • Cannabidiol